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ABSTRACT
Survival of patients with germ-cell cancer (GCC) and primary progression or relapse after cisplatin-based
ﬁrst-line chemotherapy is highly heterogeneous, ranging from close to zero to more than 70%. We
investigated b-1,4-Galactosyltransferase-I (B4GALT1) expression levels in peripheral lymphocytes in a
cohort of 46 testicular cancer patients. B4GALT1 enhances immune cell crosstalk via glycosylation of
surface molecules. A high expression level of B4GALT1 in T-lymphocytes, but not in monocytes, was
associated with a lower risk of relapse with a hazard ratio (HR) of 0.66 (95% conﬁdence interval (CI) of HR:
0.45-0.97; p D 0.02) upon multivariate Cox regression analysis. Correspondingly, interleukin 10 (IL10), a
cytokine released by cytotoxic T-cells, was likewise signiﬁcantly elevated in T-lymphocytes of non-relapse
GCC patients (HR: 0.3; 95% CI of HR: 0.14-0.65; p D 0.002). Our data indicate that glycosylation and
activation of T-lymphocytes may play a pivotal role in disease control in GCC patients with primary
progressive or relapsed disease.
KEYWORDS
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Introduction
Testicular cancer occurs in young to middle-aged male patients
and can be cured even in metastatic disease, after progression or
relapse. The 3-year overall survival (OS) probability of patients
with progression or relapse after a ﬁrst-line cisplatin-based chemo-
therapy regimen ranges between close to zero and 70% ormore.1
Salvage treatment consists either of four cycles of conven-
tional-dose chemotherapy (CDCT) or high-dose chemotherapy
(HDCT) with autologous stem cell reinfusion (ASCR)2 fol-
lowed by residual tumor resection if needed. The score of the
International Prognostic Factor Study Group (IPFSG) helps to
predict relapse and survival according to tumor marker levels
of alpha fetoprotein (AFP) and human chorionic gonadotropin
(HCG) as well as clinical parameters such as primary tumor
site, response to ﬁrst-line treatment, progression-free time
interval, presence of liver, bone and brain metastases and his-
tology, namely seminoma and non-seminoma. The score
ranges from -1 to 3 points, deﬁning very low (-1 point), low (0
points), intermediate (1 point), high (2 points) and very high (3
points) risk categories in respect to progression free survival.3
As T-cell function is important for disease control in cancer
patients4,5 and little is known about mechanisms of disease
control in germ cell-cancer (GCC) patients, we sought to retro-
spectively identify immunomodulatory properties in T-lym-
phocytes and monocytes derived from samples of stored
leukapheresis products. All products had been obtained prior
to HDCT by mobilization with chemotherapy plus granulocyte
colony-stimulating factor (G-CSF) and frozen for subsequent
ASCR. Lymphocytes and monocytes were isolated from thawed
samples via ﬂow cytometry based cell sorting.
We particularly focused on b-1,4-Galactosyltransferase-I
(B4GALT1) gene expression levels which were reported to be
highly relevant for disease control in stage I non-small-cell-lung
cancer (NSCLC) patients.6 B4GALT1 is a type II membrane-
bound glycoprotein, which exclusively transfers UDP-galactose
to different acceptor sugar molecules and is of particular impor-
tance for the interaction and adhesion of immune cells,7 either
through binding to appropriate glycoside substrates on adjacent
cell surfaces or modiﬁcation of N-acetylglucosamine (GlcNAc)
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residues of surface molecules such as leucocyte integrins.8,9 The
mRNA exists in two isoforms.10,11 In our study we focused on the
longer transcript variant coding for a surface membrane protein.
B4GALT1 seems to be important for B-cell function and migra-
tion12 and in B-cell malignancies.13 Furthermore, B4GALT1may
represent a novel biomarker in colorectal cancers that is regulated
by DNA promotor methylation14 and predicts adverse outcome
in non-metastatic clear cell renal cell carcinoma.15
Because selectins and leucocyte integrins are modiﬁed by
B4GALT1 and play a substantial role in tumor control,6 we
additionally measured the protein levels of very late antigen 4
(VLA4; CD49 d), platelet endothelial cell adhesion molecule 1
(PECAM1; CD31) and chemokine receptor 4 (CXCR4; CD184)
on peripheral lymphocytes and monocytes in GCC patient
samples via ﬂow cytometry but did not ﬁnd an association with
relapse-free survival in our patient cohort. Association of IL10
expression in T-lymphocytes with relapse-free survival and up-
regulation of B4GALT1 after lectin stimulation in vitro sup-
ports the notion that activated lymphocytes are involved in
tumor surveillance in GCC.
Here we demonstrate for the ﬁrst time that a high mRNA
expression level of B4GALT1 in peripheral blood T-lympho-
cytes derived from leukapheresis products correlates with a
lower risk of relapse in patients with GCC, who had undergone
HDCT followed by ASCR. To our knowledge, the prognostic
impact of B4GALT1 expression in T-lymphocytes in patients
with GCC has not been reported so far.
Methods
Patients and sample preparation
Between May 1999 and January 2012, a total of 73 patients with
progressive or relapsed GCC after cisplatin-based ﬁrst-line che-
motherapy were treated at the Department of Hematology,
Oncology and Immunology, University Hospital Marburg with
single or sequential HDCT and ASCR. Of 46/73 patients, ali-
quots of leukapheresis products were available and cell counts
were sufﬁciently high for analysis. Among these patients, 27/
46 had been treated within a multicenter, randomized phase III
clinical trial.16 Upon a patient’s written informed consent leu-
kapheresis products were collected after mobilization with che-
motherapy and G-CSF, frozen in 10% dimethyl sulfoxide (Carl
Roth GmbH, Karlsruhe, Germany) and stored in liquid nitro-
gen prior to be used as ASCR after HDCT. For quality assur-
ance and research purpose several 1 ml samples of the
leukapheresis products were stored separately. Subsequently, all
patients received HDCT followed by ASCR. HDCT consisted
of three cycles carboplatin (1,500 mg/m2) and etoposide
(1,500 mg/m2) per cycle in 22/27 patients. Due to renal
impairment 4/27 patients received three HDCT cycles at a
reduced dose of carboplatin (1,200 mg/m2) and etoposide
(1,200 mg/m2) per cycle as requested by the study protocol.16
1/27 patients was randomized to a single cycle of HDCT with
carboplatin (2,200 mg/m2), etoposide (1,800 mg/m2) and cyclo-
phosphamide (6,400 mg/m2).16 Outside of the study protocol,
15/46 patients were treated on an individual basis with pacli-
taxel (225 mg/m2), cisplatin (100 mg/m2), etoposide (750 mg/
m2) and ifosfamide (10 g/m2).17 Exact data about the
chemotherapy dosages were unavailable for 4/46 patients. A
single HDCT was used in 17/46 patients, two HDCT cycles
were used in 2/46 patients, and three HDCT cycles were used
in 27/46 patients.
For analysis, leukapheresis aliquots were thawed and imme-
diately resuspended in 5 ml of sodium chloride solution (0.9%)
with 5% human serum albumin (HSA) (CSL Behring, Marburg,
Germany). All steps were performed on ice. Density centrifuga-
tion with Ficoll-Paque Plus (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) at 4C was performed in order to extract
mononuclear cells (MNC). After washing with sodium chloride
solution (0.9%) containing 5% HSA, cells were resuspended in
1 ml phosphate buffered saline (PBS). 100 ml of the cell suspen-
sion were used for RNA isolation from total MNC with peq-
GOLD TriFast (peqlab, Erlangen, Germany) according to the
manufacturer’s instructions. MNC obtained from buffy coats of
healthy donors were treated with 1 mg/ml Concanavalin A
(Con A) in RPMI medium for 24 h at 37C prior to cell sorting.
Flow cytometric analysis
The remaining cells were pelleted and the following antibod-
ies were added: CD3 (UCHT1) conjugated with V450, CD31
(M89D3) with Alexa Fluor 488, CD184 (12G5) with Phyco-
erythrin or BD MultitestTM CD3/16/56/45/19 (all BD Bio-
sciences, San Jose, USA), CD14 (T€UK4) with Peridinin
Chlorophyll (PerCP) and CD49 d (MZ18-24A9) with Allo-
phycocyanin (both Miltenyi Biotec, Bergisch Gladbach,
Germany). The suspension was incubated for 30 min in the
dark at 4C and cells were suspended in 400 ml of PBS after
washing with PBS. Cells and reagents were continuously kept
on ice. 1 ml of Sytox Blue Dead Cell Stain (Molecular Probes,
Eugene, USA) was added immediately before measurement
with a MoFlo ﬂow cytometer (Beckman Coulter, Brea, Cali-
fornia, USA). For analysis and sorting, exclusion of debris
was done with forward scatter versus side scatter gating
(Fig. 1a). Employing CD14 versus CD3 gating, vital T-cells
(left upper black gate in Fig. 1b) and vital monocytes (lower
right black gate in Fig. 1b) were sorted into separate tubes
containing cold peqGOLD Trifast reagent (peqlab, Erlangen,
Germany). RNA extraction was performed directly after
sorting according to the manufacturer’s instructions. RNA
samples were stored at -80C.
Real-time PCR
cDNA was obtained employing the Omniscript RT Kit
(Qiagen, Hilden, Germany). RT-PCR for the target genes
B4GALT1 (primer sequences forward: 5ˈ-tgaccataatgcgta-
caggtg-3 ' and reverse: 5ˈ-ccaaaatactgaacataaggtaggc-3ˈ) and
IL10 (forward: 5ˈ-agaacctgaagaccctcaggc-3ˈ and reverse: 5
ˈ-ccacggccttgctcttgtt-3ˈ; internal control gene: abl forward: 5
ˈ-tcatgaaagagatcaaacacccta-3ˈ and reverse 5ˈ-catgaactcagtgat-
gatatagaacg-3ˈ) was performed in the CFX96 Real-time sys-
tem device (Bio-Rad, Munich, Germany) using the SYBR
Green PCR Master Mix assay (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. Ampliﬁcations
included one step at 95C for 15 min, followed by 45 cycles
of 94C for 15 s, 59C for 30 s and 72C for 30 s for
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B4GALT1 RT-PCR. For IL10 RT-PCR, the annealing tem-
perature was 60C. For ampliﬁcation of human interferon
gamma (IFNG), the RT2` qPCR Primer Assay for Human
IFNG (Qiagen, Hilden, Germany) was used. Primer anneal-
ing was done at 58C and human glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) was used as an internal
control gene (forward: 5 '-ctcctccacctttgacgctg-3 ' and
reverse: 5 '-accaccctgttgctgtagcc-3 '). RT-PCR data were ana-
lyzed using a standard curve and the DDCt-method. Gene
speciﬁc signals were normalized to internal control signals
from the same samples, respectively.
Statistical analyses
Means of the ﬂuorescence signals and cell counts were calcu-
lated with FlowJo 7.6.5 software (FlowJo LLC, Ashland, Ore-
gon, USA) and graphs were created with GraphPad Prism
5.02 software (GraphPad software Inc., San Diego, California,
USA).
In a ﬁrst step prognostic relevance was investigated with
univariate Cox proportional hazard models for each biomarker.
As for some biomarkers the distributions of the observed values
were positively skewed, their values were log-transformed.
Additionally, each marker was dichotomized at the median and
Kaplan-Meier curves were created for the two groups with low
and high marker values. The curves were compared using the
log-rank test. In a second step, multivariate Cox proportional
hazard models with covariates international prognostic factor
score and number of transplantations were ﬁtted for each
biomarker signiﬁcant in univariate analysis (Table 1). All these
analyses were performed using the statistical analysis software
R (www.r-project.org, version 3.2.3). Differences with a proba-
bility of p  0.05 were considered statistically signiﬁcant and
indicated with a.
Results and discussion
To the current state of knowledge immunomodulatory treat-
ment approaches are not applied in GCC but at least little suc-
cess has been reported with checkpoint inhibitor treatment in
platinum refractory disease state.18 In order to address the issue
of immunosurveillance, patients were retrospectively grouped
according to their remission status after HDCT. Among all
patients, 27/46 (58.7%) remained relapse-free after HDCT. The
median follow-up period in this patient cohort was 90 months
(range 15 to 168). The remaining 19/46 patients (41.3%) suf-
fered from relapses after HDCT (median 6 months, range 1 to
22).
We applied the IPFSG score to our patient cohort as fol-
lows: 2/46 patients underwent HDCT primarily and could
not be grouped according to the IPFSG score. Score calcula-
tion was also not possible for 4/46 patients because of miss-
ing data. 26 of the remaining 40 patients received HDCT at
ﬁrst relapse or upon progression. 5/40 patients (12.5%) with
a score of 0 were classiﬁed as “good” and 10/40 (25%) with
a score of 1 were classiﬁed as “intermediate”. 11/40 patients
with a score of 2 (high risk) and 3 (very high risk) points
were combined in one group and their prognosis was
Figure 1. Gating strategy applied for cell sorting with further RT-PCR analysis of B4GALT1 and IL10 expression levels in compartments of MNC from leukapheresis prod-
ucts. (A) Forward scatter versus side scatter gating for exclusion of debris. (B) CD14 versus vital stain gating for the exclusion of dead cells (grey gate). CD14 versus CD3
plotting in order to identify CD3-positive T-cells (upper left black gate) and CD14-positive monocytes (lower right black gate). (C) B4GALT1 levels in peripheral blood T-
lymphocytes are signiﬁcantly higher in patients with no relapse compared to those patients with relapse (Mann-Whitney-test, p D 0.008). Neither B4GALT1 levels in (D)
monocytes (pD 0.251), and (E) unsorted MNC samples (p D 0.650), nor (F) IL10 expression levels in T-cells (p D 0.178) are signiﬁcantly different upon Mann-Whitney-test-
ing. Plots show mean and standard deviation, respectively. FSC: forward scatter; MNC: mononuclear cells; ns: not signiﬁcant; SSC: side scatter.
ONCOIMMUNOLOGY e1423169-3
classiﬁed as “poor”. In addition, all patients who received
HDCT after second or subsequent relapse (14/40) were also
classiﬁed as “poor” apart from the score calculation, result-
ing in 25/40 patients in this group (62.5%).19 Patient data
are depicted in detail in Table 2. Analysis of distributions
of T-lymphocytes and monocytes were performed by ﬂow
cytometry and revealed no differences in the compartments
between the two patient groups with or without relapse
after HDCT (Fig. 1a and b and Fig. S1a and b). We also
determined the expression levels of surface molecules
Table 1. Difference in relapse-free survival was calculated with the Cox regression model.
Univariate Cox-Models Multivariate Cox-Model for B4GALT1 T-cells Multivariate Cox-Model for IL10 T-cells
Covariate HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
B4GALT1 T-cells 0.62 (0.42,0.91) 0.02 0.66 (0.45,0.97) 0.03
log IL10 T-cells 0.62 (0.39,1) 0.05 0.3
(0.14,0.65)
0.002
NoTx 0.21 0.008
1 reference reference
2 3.02 (0.3,30.87) 0.22 (0.02,2.35)
3 0.51 (0.17,1.47) 0.04 (0.01,0.3)
IPFSG score class 0.53 0.24
good reference reference
intermediate 2.54 (0.26,24.74) 5.9 (0.42,83.77)
poor 3.25 (0.4,26.15) 7.43 (0.71,77.44)
Further PCR measurements
log BaGALT1 Mono 1 (0.99,1.01) 0.77
log B4GALT1 MNC 1.02 (0.98,1.05) 0.37
log IL10 Mono 0.93 (0.76,1.16) 0.54
Cytometric measurements
log CD31 T-cells 1.27 (0.84,1.93) 0.26
log CD49 d T-cells 1 (0.99,1.01) 0.93
log CD184 T-cells 11,1 0.43
log Cd31 Mono 0.45 (0.25,0.79) 0.01
log Cd49 d Mono 0.97 (0.58,1.63) 0.92
log CD184 Mono 0.6 (0.23,1.61) 0.31
In the multivariate analysis B4GALT1 mRNA expression levels in T-lymphocytes had a signiﬁcant inﬂuence on the RFS (pD 0.03). The IPFSG score and the number of trans-
plantations did not inﬂuence survival in our patient cohort. For IL10 mRNA expression levels in T-lymphocytes the multivariate analysis also showed a signiﬁcant impact
on the RFS (p D 0.002).
CI: conﬁdence interval of the hazard ratio; HR: hazard ratio; IPFSG: International Prognostic Factor Study Group; Tx: transplantation.
Table 2. Patients’ characteristics.
Relapse
[ALL]
N D 46
No
N D 27
Yes
N D 19 N
Patients
Follow-up time months (median)
[min; max]
29
[1; 168]
90
[15; 168]
6
[1; 22]
44
IPFSG Score Class: 40
Good (0) 5 (12.5%) 4 (10.0%) 1 (2.5%)
Intermediate1 10 (25.0%) 6 (15.0%) 4 (10.0%)
Poor2-3 and 2nd relapse 25 (62.5%) 13 (32.5%) 12 (30.0%)
No. of HDCT/SCT 46
1 17 (37.0%) 7 (25.9%) 10 (52.6%)
2 2 (4.3%) 1 (3.7%) 1 (5.3%)
3 27 (58.7%) 19 (70.4%) 8 (42.1%)
Gene expression levels
B4GALT1_T-cells 2.57 § 1.98 3.40 § 2.22 1.60 § 1.08 37
log.IL10_T-cells 0.58 § 1.40 1.08 § 1.36 0.04 § 1.30 25
log.B4GALT1_Mono 0.61 § 0.99 0.42 § 0.95 0.86 § 1.01 44
log.IL10_Mono 3.02 § 1.41 3.02 § 1.40 3.02 § 1.47 38
log.B4GALT1_MNC 0.64 § 0.72 0.68 § 0.75 0.58 § 0.70 32
Protein expression levels
log.CD31_T-cells 4.36 § 0.89 4.33 § 0.59 4.39 § 1.21 46
log.CD49 d_T-cells 3.65 § 0.50 3.68 § 0.50 3.61 § 0.51 46
log.CD184_T-cells 3.91 § 1.02 3.81 § 1.24 4.05 § 0.58 46
log.CD31_Mono 6.39 § 0.58 6.33 § 0.44 6.46 § 0.73 46
log.CD49 d_Mono 4.26 § 0.43 4.20 § 0.46 4.33 § 0.38 46
log.CD184_Mono 5.68 § 1.06 5.54 § 1.33 5.89 § 0.44 46
Number of samples analyzed, median follow-up period, IPFSG scores, number of HDCT cycles, gene and protein expression levels are depicted. The patients were divided
into groups with and without relapse. Score calculation was not possible for 6/46 patients: For 4/46 patients no follow-up data were available, 2/46 patients underwent
primary HDCT.
HDCT: high-dose chemotherapy; IPFSG: International Prognostic Factor Study Group; SCT: stem cell transplantation.
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related to cell adhesion on both T-cells and monocytes, but
did not ﬁnd any difference in the expression levels of
PECAM-1, VLA-4 and CXCR4 between the patient groups
with and without relapse after HDCT, as depicted in
Fig. S2. Measuring the basal expression level of B4GALT1 in
different peripheral blood lymphocyte populations from healthy
donors, we show that B-lymphocytes exhibit higher basal
B4GALT1 transcript levels compared to T-lymphocytes or NKT-
cells (Fig. S3a). Furthermore, granulocytes responded to G-CSF
treatment with an induced expression of B4GALT1 in vitro but
lymphocyte subpopulations did not exhibit B4GALT1 alteration
after treatment with G-CSF in vivo or in vitro (Fig. S4). After
separation of T-lymphocytes and monocytes from MNC by ﬂow
cytometry based cell sorting (Fig. 1a and b) we performed RT-
PCR in order to determine B4GALT1 mRNA expression levels
in those cell-subsets in our cohorts of GCC patients. Within the
T-cell population the expression level of B4GALT1 was found to
be signiﬁcantly higher (p D 0.008) in the group of patients with-
out relapse after HDCT compared to the group of patients who
experienced a further relapse after HDCT (Fig. 1c) upon Mann
Whitney testing. Comparison of non-relapse versus relapse
patients by univariate Cox regression analyses showed a hazard
ratio (HR) for the risk of relapse of 0.62 (95% conﬁdence interval
(CI) of HR: 0.42-0.91, p D 0.02) (Table 1). However, we could
not ﬁnd a signiﬁcant difference in B4GALT1 expression levels
within the monocyte population (Fig. 1d and Table 1) or total
MNC (Fig. 1e and Table 1). Thus, only B4GALT1 mRNA
expression in T-lymphocytes was signiﬁcantly associated with
durable disease remission.
In order to substantiate our hypothesis that activated
peripheral T-cells may be involved in disease control of GCC,
we performed lectin stimulation of MNC with Concanavalin
A (Con A) in vitro and found up-regulation of B4GALT1
mRNA particularly in the CD4C T-lymphocyte fraction (Fig.
S3b). Furthermore, we determined the mRNA expression lev-
els of IL10 as a marker for T-cell activation via qPCR analysis
in our samples. Upon univariate Cox regression analysis we
found IL10 to be signiﬁcantly higher expressed in T-lympho-
cytes from leukapheresis products of patients without relapse
after HDCT in comparison to the relapsed group (HR: 0.62;
95% CI of HR: 0.39-1.0; p D 0.05) (Table 1). No difference in
IL10 expression was detectable in monocytes or total MNC
between patients with or without relapse after HDCT
(Table 1). A subgroup of patients was also evaluated for
Figure 2. Relapse-free survival rates in 46 relapsed germ cell cancer patients with respect to the number of HDCT and ASCR, the international prognostic factor score,
B4GALT1 and IL10 expression levels. (A) RFS is not signiﬁcantly different in patients with one (black line), two (grey line) or three (dotted line) SCT cycles (log-rank test, p
D 0.055). (B) Analysis of patients’ RFS according to the IPFSG categories. Patients with a good prognosis score (i.e. 0; black line) were compared to those with an interme-
diate (i.e. 1; grey line) and poor prognosis score (i.e. 2–3 and 2nd relapse; dotted line). RFS is not signiﬁcantly different between these groups (log-rank test, p D 0.420).
(C) RFS is signiﬁcantly higher in patients with high T-cell B4GALT1 mRNA expression levels (grey line) compared to those with low levels (black line) (log-rank test, p D
0.044). High and low refer to values above and below the median value, respectively. (D) RFS is signiﬁcantly higher in patients with high IL10 mRNA expression levels
(grey line) compared to those with low levels (black line) (log-rank test, p D 0.015). IPFSG: International Prognostic Factor Study Group; RFS: relapse-free survival; SCT:
stem cell transplantation.
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expression of interferon gamma (IFNG) in CD4C and CD8C
cells. Although up-regulation of IFNG in lymphocytes of
healthy donors was observed after in vitro Con A stimulation
we found no difference in IFNG expression between the
relapsed patients and those with persistent remission (Fig. S5).
For further corroboration we performed a multivariate Cox
regression analysis with regard to the number of cycles of high-
dose chemotherapy in single or sequential HDCT and to the
prognostic score of good versus poor prognosis.20 Among
patients with a high B4GALT1 expression in T-lymphocytes
the HR for relapse-free survival (RFS) was 0.66 (95% CI of HR:
0.45-0.97; p D 0.03). IL10 expression in T-lymphocytes also
proved to be an independent prognostic parameter as calcu-
lated by the multivariate Cox model with an HR of 0.3 (95% CI
of HR: 0.14-0.65; p D 0.002). The corresponding graphs for
log-rank testing are depicted in Fig. 2. Applying the prognostic
score to our cohort resulted in an improved RFS between the
good, intermediate or poor prognosis groups, but this did not
reach statistical signiﬁcance, possibly due to low patient
numbers.
Next, we sorted lymphocyte subpopulations from a second
independent cohort of 19 GCC patients, dividing CD4C and
CD8C cells. As in healthy individuals we observed a twofold
higher B4GALT1 gene expression in B-lymphocytes compared
to T-lymphocytes (data not shown) and found a difference of
B4GALT1 expression levels between relapse and non-relapse
GCC patients in CD8C cells but not in CD4C cells (Fig. S6a
and b). A trend toward better survival of the group with high
B4GALT1 expression in CD8C cells was observed also in this
second patient cohort, but log-rank testing did not give statis-
tical signiﬁcance for RFS (p D 0.13) or overall survival (p D
0.08), possibly due to the relatively small number of samples
(Fig. S6c and d).
Thus, our data clearly support the notion that B4GALT1
expression levels in T-lymphocytes denote a novel biomarker
for the prognosis of GCC patients undergoing salvage HDCT
and that activated T-lymphocytes may be involved in tumor
control in such patients.
Immunohistochemistry (IHC) staining revealed moderate
inﬁltration of B4GALT1 expressing T-cells in the tumor tissue.
Teratocarcinoma cells expressed more B4GALT1 protein than
cells of pure seminomas (Fig. S7 and Table S1). Given the up-
regulation of epidermal growth factor receptor (EGFR) signal-
ing pathways in GCC21 and B4GALT1 mediated inhibition of
EGFR signaling in hepatocellular carcinoma,22 it could be
assumed hypothetically that B4GALT1 expression renders lym-
phocytes potent to exert immunosurveillance, perhaps via
interference with EGFR dimerization or phosphorylation.
We conclude that B4GALT1 expression levels in T-lym-
phocytes from leukapheresis products of patients with GCC
scheduled for salvage HDCT and ASCR seem to be relevant
for tumor control and may represent a novel candidate bio-
marker in such patients. As our study was performed retro-
spectively and in relapse patients scheduled for salvage
HDCT, who had already undergone chemotherapy, expres-
sion of B4GALT1 should be evaluated prospectively and may
include also patients at initial diagnosis, especially in order to
see if the preceding chemotherapy and stimulation with G-
CSF have altered the B4GALT1 expression levels. Moreover,
strategies of T-cell modulation particularly in patients with
low B4GALT1 expression levels in T-lymphocytes may be
worthwhile to be studied in further clinical trials.
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